Does exercise help after liraglutide ends? Reading the S-LiTE trial

What question did the study ask?

This is an evidence explainer about a 2024 paper, not a new research announcement. The question is whether a treatment programme leaves benefits that remain after the programme ends. That is different from asking how much weight people lose while treatment continues, or whether a person should change their medication.

The protocol enrolled adults aged 18–65 with BMI 32–43 and excluded diabetes and serious chronic illness. Participants first completed a supervised low-calorie diet, then entered exercise, liraglutide, combined treatment or placebo groups. That selection matters when applying results to someone with a different starting point. [2]

Put the comparison on the correct timeline

Draw three boxes when reading this kind of paper: before randomisation, the treatment period, and the period after treatment. Write the start and end of the reported comparison beneath them. A result spanning the last two boxes combines what happened during treatment with what happened afterwards.

The follow-up's 5.1 kg difference favoured prior combined treatment over liraglutide alone from randomisation to the final assessment. That covered both years and did not meet the prespecified false-discovery-rate threshold. The off-treatment regain difference was 2.5 kg, with a 95% confidence interval from −1.5 to 6.5 kg. That interval includes no difference. [1]

These are different questions. Do not relabel a combined-period result as “extra weight regain prevented after stopping”. Also, an interval including no difference does not establish that the approaches are equivalent; it shows uncertainty in that particular comparison.

Was this a resistance-training trial?

The protocol described supervised cycling plus circuit work, individual aerobic activity and a gradual introduction. It was a mixed exercise programme, not a comparison isolating resistance training. A protocol explains the intended intervention; it does not prove that it was effective. [2]

When you see “exercise” in a headline, ask what people actually did, how often support was available and what equipment was involved. A gym membership, a walking reminder and a structured supervised programme are different services. Do not assume that sharing the word exercise makes their results interchangeable.

That distinction helps when choosing what to discuss with your care team. You can ask about strength instruction and aerobic activity separately, without trying to copy a research programme designed for selected participants.

What makes the follow-up uncertain?

Of 195 randomised participants, 109 attended follow-up; missing outcomes were modelled. Treatment had ended and behaviour afterwards was not newly randomised. The study tested liraglutide, so it cannot establish the same effect for semaglutide or tirzepatide. [1]

The pattern is worth studying, but a claim about which habit caused later success needs more than an observation after support ends. Ask whether an analysis compares original allocations, actual attendance or later behaviour. Those comparisons have different meanings. Avoid turning a description of what successful participants did into a promise that anyone doing it will get the same result.

Funding and relationships also belong in the interpretation: Helsefonden and the Novo Nordisk Foundation funded the follow-up, and the paper discloses pharmaceutical-industry relationships among some authors. That context calls for careful reading rather than automatic acceptance or dismissal. [1]

Use a four-question evidence card

Copy this original reading tool: Which people? Which intervention? Which comparison period? Which uncertainty? Fill it in before using a number from an article or sharing a headline. Add a separate line for what the evidence does not answer. The card is a reading aid, not a validated clinical instrument.

For a worked example, imagine a fictional coaching study reports better results at month 24 after a year of coaching. Ask whether the difference arose during coaching, after coaching or both. Then ask whether the study compared coaching with no coaching, a different coach or a different treatment. This example uses no actual result; it demonstrates why a date and comparator belong beside a number.

The same approach works for body-composition reports. Write the actual measured outcome on the card. If it says body weight or body-fat percentage, keep that wording. Do not silently substitute muscle strength, physical function or a personal health outcome.

Turn the evidence into a maintenance conversation

Bring questions rather than a stopping plan: What support should continue if access to treatment changes? Who can help with exercise instruction? Which observations would my clinician find useful? What arrangements make the existing activity plan workable outside supervised sessions? These questions are practical suggestions, not interventions proven by S-LiTE.

General US guidance includes aerobic and muscle-strengthening activity; these are complementary categories. It is population guidance, not a prescription for preventing regain after medication ends. [3]

Choose one logistical issue to address with the appropriate professional: finding a suitable session time, understanding the existing exercises or arranging follow-up. Decisions about medication continuation or changes stay with your prescriber. The research gives a reason to discuss coordinated maintenance support, without supplying an assured result or a Peptis treatment claim.

Does S-LiTE prove exercise prevents regain after a GLP-1 ends?

No. The follow-up offers useful evidence, but the relevant comparisons, incomplete attendance and statistical uncertainty limit that claim.

Can I apply the result directly to semaglutide or tirzepatide?

No. The drug studied was liraglutide. This study alone cannot establish the effect with other medications.

Was the exercise programme only strength training?

No. It mixed cycling, circuit training and individual aerobic activity.